PIPELINE
Marketed Products
Two innovative therapies utilizing Kala’s proprietary AMPPLIFY® Drug Delivery Technology to address medical needs for front of the eye
First and only prescription therapy specifically for the short-term management
of the signs and symptoms of dry eye disease
First and only BID corticosteroid indicated for the treatment of post-operative ocular inflammation and pain
Internal Pipeline
Proprietary NCE development programs
targeted to address
front and back
of the eye diseases
| Discovery | Lead Optimization |
Candidate Selection | Formulation Development | IND- Enabling Studies |
Clinical Studies | |
|---|---|---|---|---|---|---|
|
Tyrosine Kinase Inhibitor Retinal diseases, including wet AMD, DME, and RVO (Formulation Development) |
||||||
|
Surface Targeting Steroid (STS) Corneal surface diseases (Formulation Development) |
||||||
|
Selective Glucocorticoid Receptor Modulator (SEGRM) Retinal diseases, including wet AMD, DME, and RVO; corneal surface diseases (Lead Optimization) |
